USFDA has approved Mavyret, the first drug to treat all forms of hepatitis C in as little as eight weeks. This drug manufactured by AbbVie Inc. is for adults without significant cirrhosis and patients whose previous treatment did not provide significant results. The current market includes two other AbbVie hepatitis C drugs, one by Merck & Co. and four by Gilead Sciences Inc.which provides more options to doctors and patients. Mavyret is priced quite below the other drugs. Maryvet combines two hepatitis C medicines, glecaprevir and pibrentasvir, taken as three pills together once a day. The most common side effects were nausea, headache, fatigue and itchy skin. In patients who previously had hepatitis B infections, treatment with Maryvet can reactivate that virus, causing potentially fatal liver problems. The study involved 2,300 adult patients who did not have cirrhosis, and for 97.5% the virus was undetectable in their blood, in eight weeks after taking Mavyret. Among patients with severe kidney damage, 98% were cured after 12 weeks.